Janssen gets 2nd rejection for Xarelto in ACS
This article was originally published in Scrip
Executive Summary
For the second time, the US FDA has rejected Janssen Research & Development's supplemental new drug application for Xarelto (rivaroxaban) as a therapy to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS).